Kestra Medical Technologies, Ltd.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | $95.1M | $59.8M | $27.8M |
| Cost of Revenue | $46.3M | $35.6M | $27.5M |
| Gross Profit | $48.9M | $24.2M | $362.0K |
| Gross Margin | 51.4% | 40.5% | 1.3% |
| Operating Expenses | |||
| Research & Development | $19.5M | $15.7M | $15.5M |
| SG&A Expense | $164.1M | $114.9M | $69.9M |
| Operating Income | $-134.7M | $-106.4M | $-85.1M |
| Operating Margin | -141.6% | -177.8% | -305.8% |
| Interest Expense | — | — | — |
| Pretax Income | $-131.3M | $-113.7M | $-94.1M |
| Income Tax Expense | $294.0K | $135.0K | $24.0K |
| Net Income | $-131.6M | $-113.8M | $-94.1M |
| Net Margin | -138.4% | -190.3% | -338.4% |
| EPS (Basic) | $-2.43 | $-2.57 | $-2.54 |
| EPS (Diluted) | $-2.43 | $-2.57 | $-2.54 |
| Shares Outstanding (Basic) | 54.2M | 49.2M | 39.8M |
| Shares Outstanding (Diluted) | 54.2M | 49.2M | 39.8M |
| Dividends Per Share | — | — | — |